ArieRegevMD

Gastroenterology • Indianapolis, IN

Hepatology & Liver Transplantation

Physician

Join to view full profile

Dr. Regev is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Regev's full profile

Already have an account?

Office
720 Eskenazi Ave

Indianapolis, IN 46202
Phone+1 317-880-8329

Fax+1 305-243-8470

Education & Training

The Hebrew University of Jerusalem Hadassah Medical SchoolClass of 1988

Certifications & Licensure

IN State Medical License 2007 - 2025
FL State Medical License 2001 - 2007

Publications & Presentations

PubMed

Review article: Recommendations for detection, assessment and management of suspected drug-induced liver injury during clinical trials in oncology patients.
Anna Fettiplace, John Marcinak, Michael Merz, Hui-Talia Zhang, Luciana Kikuchi
Alimentary Pharmacology & Therapeutics. 2024-11-01
Safety, Tolerability, and Pharmacokinetics of an Oral Small Molecule Inhibitor of IL-17A (LY3509754): A Phase I Randomized Placebo-Controlled Study.
Amita Datta-Mannan, Arie Regev, David E Coutant, Andrew J Dropsey, Joanne Foster
Clinical Pharmacology and Therapeutics. 2024-05-01
Correction to: Drug-Induced Liver Injury in the Elderly: Consensus Statements and Recommendations from the IQ-DILI Initiative.
Eric B Cohen, Meenal Patwardhan, Ritu Raheja, David H Alpers, Raul J Andrade
Drug Safety. 2024-05-01

Other

Diagnosis and management of cystic lesions of the liver
Regev A, Reddy KR
http://www.uptodate.com/contents/diagnosis-and-management-of-cystic-lesions-of-the-liver
UpToDate, Wolters Kluwer Health - 2013-03-22

Press Mentions

Consensus: Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Patients with Nonalcoholic SteatohepatitisFebruary 13th, 2020
Drug-Induced Steatosis and Steatohepatitis: The Search for Novel Serum Biomarkers Among Potential Biomarkers for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic SteatohepatitisFebruary 14th, 2019